Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.18−0.15 (-11.28%)
Close on Nov 13, 2026Market cap $118.40MP/E –Yield –
Cellectis gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 100.0%, against 100.0% the year before. The highest annual figure on record is 100.0% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | +0.0 |
| FY2024 | Dec 31, 2024 | 100.0% | +97.6 |
| FY2023 | Dec 31, 2023 | 2.4% | −88.4 |
| FY2022 | Dec 31, 2022 | 90.8% | −3.2 |
| FY2021 | Dec 31, 2021 | 93.9% | −2.3 |
| FY2020 | Dec 31, 2020 | 96.2% | +71.2 |
| FY2019 | Dec 31, 2019 | 25.0% | −53.5 |
| FY2018 | Dec 31, 2018 | 78.5% | −11.1 |
| FY2017 | Dec 31, 2017 | 89.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | 69.1% | +39.8 |
| Q2 FY2022 | Jun 30, 2022 | 74.8% | – |
| Q2 FY2021 | Jun 30, 2021 | -5.2% | – |
| Q2 FY2020 | Jun 30, 2020 | -100.9% | – |
| Q2 FY2019 | Jun 30, 2019 | 29.3% | – |
See a number that looks wrong?